205 related articles for article (PubMed ID: 25885745)
1. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF
BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
[TBL] [Abstract][Full Text] [Related]
2. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF; Freeman JL; Orihuela E; Goodwin JS
J Clin Oncol; 2007 Dec; 25(34):5359-65. PubMed ID: 18048816
[TBL] [Abstract][Full Text] [Related]
4. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
Gilbert SM; Kuo YF; Shahinian VB
Urol Oncol; 2011; 29(6):647-53. PubMed ID: 19926311
[TBL] [Abstract][Full Text] [Related]
5. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.
Kuykendal AR; Hendrix LH; Salloum RG; Godley PA; Chen RC
Ann Oncol; 2013 May; 24(5):1338-43. PubMed ID: 23277483
[TBL] [Abstract][Full Text] [Related]
6. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
J Natl Cancer Inst; 2006 Jun; 98(12):839-45. PubMed ID: 16788157
[TBL] [Abstract][Full Text] [Related]
7. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
Wagle DG
N Engl J Med; 2011 Feb; 364(6):579; author reply 580. PubMed ID: 21306259
[No Abstract] [Full Text] [Related]
8. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
9. Urologist Practice Structure and Spending for Prostate Cancer Care.
Modi PK; Herrel LA; Kaufman SR; Yan P; Borza T; Skolarus TA; Schroeck FR; Hollenbeck BK; Shahinian VB
Urology; 2019 Aug; 130():65-71. PubMed ID: 31029672
[TBL] [Abstract][Full Text] [Related]
10. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF
J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
[TBL] [Abstract][Full Text] [Related]
11. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
12. National Trends in the Utilization of Androgen Deprivation Therapy for Very Low Risk Prostate Cancer.
May A; Henke J; Au D; Raza SJ; Davaro F; Hamilton Z; Siddiqui SA
Urology; 2019 Aug; 130():79-85. PubMed ID: 31047912
[TBL] [Abstract][Full Text] [Related]
13. Trends in outpatient MRI seem to reflect recent reimbursement cuts.
Levin DC; Rao VM; Parker L
J Am Coll Radiol; 2015 May; 12(5):463-6. PubMed ID: 25448060
[TBL] [Abstract][Full Text] [Related]
14. Urologist-Level Correlation in the Use of Observation for Low- and High-Risk Prostate Cancer.
Tyson MD; Graves AJ; O'Neil B; Barocas DA; Chang SS; Penson DF; Resnick MJ
JAMA Surg; 2017 Jan; 152(1):27-34. PubMed ID: 27653425
[TBL] [Abstract][Full Text] [Related]
15. Bone density testing among prostate cancer survivors treated with androgen-deprivation therapy.
Morgans AK; Smith MR; O'Malley AJ; Keating NL
Cancer; 2013 Feb; 119(4):863-70. PubMed ID: 23065626
[TBL] [Abstract][Full Text] [Related]
16. Variation in Practice Patterns and Reimbursements Between Female and Male Urologists for Medicare Beneficiaries.
Nam CS; Mehta A; Hammett J; Kim FY; Filson CP
JAMA Netw Open; 2019 Aug; 2(8):e198956. PubMed ID: 31397864
[TBL] [Abstract][Full Text] [Related]
17. Reimbursement policy and androgen-deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF; Gilbert SM
N Engl J Med; 2010 Nov; 363(19):1822-32. PubMed ID: 21047226
[TBL] [Abstract][Full Text] [Related]
18. Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse.
Ellis SD; Nielsen ME; Carpenter WR; Jackson GL; Wheeler SB; Liu H; Weinberger M
Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):173-81. PubMed ID: 25849354
[TBL] [Abstract][Full Text] [Related]
19. Medical androgen deprivation therapy and increased non-cancer mortality in non-metastatic prostate cancer patients aged ≥66 years.
Abdollah F; Sammon JD; Reznor G; Sood A; Schmid M; Klett DE; Sun M; Aizer AA; Choueiri TK; Hu JC; Kim SP; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur J Surg Oncol; 2015 Nov; 41(11):1529-39. PubMed ID: 26210655
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices.
Wasson JH; Fowler FJ; Barry MJ
J Urol; 1998 Jun; 159(6):1993-6; discussion 1996-7. PubMed ID: 9598505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]